HDAC2 as a therapeutic target in bladder cancer: insights into the altered epigenetic regulation and lysine lactylation
Collectively, these findings suggest the pivotal role of HDAC2 in epigenetic modulation and lysine lactylation, and underscore HDAC2 as a promising therapeutic target in BCa.
Authors
- Junlong Zhuang (ORCID: https://orcid.org/0000-0001-5150-3669)
- Shuting Fang
- Minghao Zheng (ORCID: https://orcid.org/0009-0008-6842-5757)
- Tianlei Xie
- Hongqian Guo
- Wei Zhao (ORCID: https://orcid.org/0000-0003-2498-1272)
- Guanghui Xu (ORCID: https://orcid.org/0000-0001-9534-214X)
- Shan Peng (ORCID: https://orcid.org/0000-0002-4432-6008)
- Shuo Liang (ORCID: https://orcid.org/0000-0001-7842-7782)
- Zhigang Wu (ORCID: https://orcid.org/0009-0002-0038-8423)
- Guang Hu (ORCID: https://orcid.org/0000-0003-4883-0866)
- Yuqin Li (ORCID: https://orcid.org/0000-0001-6188-8590)
- Yihua Zhou
- Wenli Diao
- Yongming Deng
Institutions
- Nanjing University of Chinese Medicine (CN)
- Chengdu Medical College (CN)
- Nanjing Drum Tower Hospital (CN)
- First Affiliated Hospital of Chengdu Medical College (CN)
- Jiangsu Province Hospital (CN)
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1186/s13046-025-03610-5
- Citations
- 1
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.81